Aprea Therapeutics, Inc. completed a private placement that raised $3.1 million in gross proceeds by selling 2,623,023 shares of common stock (or pre‑funded warrants) and accompanying warrants to purchase an equal number of shares. The offering was priced at‑the‑market under Nasdaq rules, with an effective price of $1.165 per share and a warrant exercise price of $1.04, reflecting the company’s current market valuation and the liquidity needs of a clinical‑stage biopharma.
The capital infusion extends Aprea’s cash runway through the first quarter of 2027. Prior to the placement, the company reported $13.7 million in cash at the end of Q3 2025, a decline from $22.8 million at the end of 2024, and an accumulated deficit of $321 million. The new funds are earmarked for general corporate purposes and research and development, providing a buffer that mitigates the company’s going‑concern risk and allows continued investment in its precision‑oncology pipeline.
Aprea’s lead DDR‑targeted candidates, APR‑1051—a WEE1 kinase inhibitor—and ATRN‑119—a ATR inhibitor—are in early clinical development. The financing is critical to support the next phases of these trials, including dose‑escalation studies and biomarker‑driven enrollment, which are essential for demonstrating clinical efficacy and attracting future partnership or acquisition interest.
Management emphasized the strategic importance of the placement. “The additional capital gives us the runway to advance APR‑1051 and ATRN‑119 through pivotal clinical milestones and to explore strategic collaborations,” said Oren Gilad, Ph.D., President and Chief Executive Officer. “It also strengthens our balance sheet and reduces the pressure on our cash reserves.”
The private placement follows a $34 million raise in March 2024, underscoring Aprea’s ongoing need for external financing to fund its R&D pipeline. While the company remains a high‑risk, high‑potential biopharma, the new capital positions it to maintain momentum in a competitive oncology landscape and to avoid the liquidity constraints that have historically challenged clinical‑stage firms.
The financing signals confidence from investors willing to support Aprea’s long‑term development strategy, and it provides the company with the financial flexibility to pursue additional funding rounds or strategic partnerships as its pipeline progresses toward regulatory milestones.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.